NCT04203160 2025-12-31
Gemcitabine and Cisplatin With or Without CPI-613 as First Line Therapy for Patients With Advanced Unresectable Biliary Tract Cancer (BilT-04)
University of Michigan Rogel Cancer Center
Phase 1/2 Terminated
Clinical Trials
3 trialsNCT00907166 2017-03-21
A Phase I/II Open-Label Dose-Escalation Clinical Trial of CPI-613 in Combination With Gemcitabine in Cancer Patients
Cornerstone Pharmaceuticals
Phase 1/2 Terminated
NCT01832857 2016-12-29
Phase 2 Safety, Tolerability and Efficacy Study of CPI-613 in Cancer Patients
Cornerstone Pharmaceuticals
Phase 2 Terminated